<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00193882</url>
  </required_header>
  <id_info>
    <org_study_id>TROG 03.01</org_study_id>
    <secondary_id>NCIC CTG ES.2</secondary_id>
    <secondary_id>TGA 2004/83</secondary_id>
    <secondary_id>NHMRC 291103</secondary_id>
    <nct_id>NCT00193882</nct_id>
  </id_info>
  <brief_title>Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.</brief_title>
  <official_title>A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and Palliation of Dysphagia in Patients Treated With Radiotherapy vs ChemoRadiotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trans-Tasman Radiation Oncology Group (TROG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the treatment of gullet cancer with radiotherapy alone and assess the advantage
      and toxicity of adding chemotherapy. The hypothesis to be tested is as follows: That the
      addition of chemotherapy to a short course of radiation treatment improves the proportion of
      patients who achieve relief of dysphagia and improves quality of life compared to radiation
      alone in patients with advanced oesophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective radical treatment trials in oesophageal cancer have shown responses in both
      radiotherapy alone and radiotherapy when combined with chemotherapy. Retrospective studies
      show a response in the palliative setting to relieve dysphagia. The response, durability and
      quality of life end points have not been previously fully documented. This will be addressed
      by this trial.

      Dysphagia is the commonest presenting symptom due to local disease obstructing the
      oesophagus. Difficulty eating not only affects the patient's ability to maintain nutrition,
      but also impacts on all areas of quality of life. Relief of dysphagia becomes the highest
      priority for treatment.

      At the time of developing this protocol there were no randomised trials comparing
      chemo-radiotherapy and radiotherapy in the palliative setting.

      Few studies have prospectively assessed quality of life data for patients with oesophageal
      cancer, and although toxicity and survival data is available, there is no long-term data on
      quality of life. This trial will assess quality of life in a consecutive manner using a
      standardised self-reporting measure of quality of life, and compare quality of life across
      two groups having different treatments.

      Eligible patients are those with proven carcinoma of the oesophagus who are deemed not
      suitable for definitive radical treatment due to the advanced nature of disease, presence of
      metastases or intercurrent illness, who have symptomatic dysphagia requiring loco-regional
      palliation.

      Patients will be randomised to the following treatment options:

        1. Radiotherapy Alone

             -  35 Gy in 15 fractions (Australia and New Zealand) or

             -  30 Gy in 10 fractions(Canada ONLY)

        2. Chemo-Radiotherapy

             -  35 Gy in 15 fractions (Australia and New Zealand) or

             -  30 Gy in 10 fractions (Canada ONLY)

             -  Cisplatin 80mg/m2 IV day 1 (or 20mg/m2/day IV days 1 - 4)

             -  5-Fluorouracil 800mg/m2/day IV days 1 - 4

      Patients will have an initial baseline assessment then be followed up weekly during
      treatment, monthly for 1 year post treatment and then 3 monthly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 7, 2003</start_date>
  <completion_date type="Actual">June 18, 2013</completion_date>
  <primary_completion_date type="Actual">March 21, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of dysphagia</measure>
    <time_frame>This will be measured at nine weeks after the start of radiotherapy and must be maintained at the next review 4 weeks thereafter.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysphagia progression free survival.</measure>
    <time_frame>This will be measured from randomisation to the time of first progression of dysphagia.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life differences post treatment and at 3 months and 6 months.</measure>
    <time_frame>post treatment and at 3 months and 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity.</measure>
    <time_frame>Interim analyses planned at 110 pateints. Final analyses will occur after 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival.</measure>
    <time_frame>Interim analyses planned at 110 pateints. Final analyses will occur after 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieving any response in dysphagia after treatment as measured by an improvement of at least 1 point on the 5 point dysphagia scale.</measure>
    <time_frame>Interim analyses planned at 110 pateints. Final analyses will occur after 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients receiving secondary treatment (radiation, chemotherapy or stenting).</measure>
    <time_frame>Interim analyses planned at 110 pateints. Final analyses will occur after 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieving a complete response i.e. dysphagia score of 0.</measure>
    <time_frame>Interim analyses planned at 110 pateints. Final analyses will occur after 5 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Esophagus Cancer</condition>
  <arm_group>
    <arm_group_label>A: Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Chemo-radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy (Cisplatin + 5-Fluorouracil ) and Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>80mg/m2 IV day 1</description>
    <arm_group_label>B: Chemo-radiotherapy</arm_group_label>
    <other_name>Cisplatin Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>35 Gy in 15 fractions</description>
    <arm_group_label>A: Radiotherapy</arm_group_label>
    <arm_group_label>B: Chemo-radiotherapy</arm_group_label>
    <other_name>Radiation</other_name>
    <other_name>Radiation Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>800mg/m2/day IV days 1 - 4</description>
    <arm_group_label>B: Chemo-radiotherapy</arm_group_label>
    <other_name>DBL Flurouracil Injection BP, Efudix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven Carcinoma of the oesophagus.

          -  Not a candidate for radical/curative treatment due to the advanced nature of the
             disease, presence of metastases, or intercurrent illness. (It should be noted that,
             patients with mediastinal nodes and no more distant disease maybe suitable for radical
             treatment).

          -  Symptomatic patients with dysphagia scores of ≥ 1 i.e. able to eat only some solids
             (see Mellow Scale appendix 1)

          -  Performance status ECOG ≤ 2

          -  Patients must begin treatment within 2 weeks of randomization.

          -  Patient is at least 18 years old.

          -  Adequate haematological function to undergo chemotherapy. Peripheral blood -
             Neutrophils &gt; 1.5 x 10^9/L - Platelets &gt; 100 x 10^9/L

          -  Adequate renal function, Creatinine - Calculated clearance ≥ 50 ml/min

          -  Patients capable of childbearing are using adequate contraception.

          -  Written informed consent of patient.

        Exclusion Criteria:

          -  Previous mega-voltage external beam Radiotherapy or brachy-therapy delivered to the
             region of the chest.

          -  Synchronous active malignancies.

          -  Pregnant or lactating patients.

          -  Patients unfit for any treatment component.

          -  Tracheo-oesophageal fistula.

          -  Stents in situ.

          -  Previous chemotherapy for Oesophageal Cancer

          -  CT scan of thorax and abdomen more than 8 weeks prior to randomization

          -  Full Blood Count, Biochemistry (including creatinine) and creatinine clearance more
             than 2 weeks prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Penniment, FRANZCR</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Adelaide Hopsital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>1871</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2069</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premion - Wesley</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology - Mater Centre</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Queensland Oncology Service</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4810</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum - Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum - Moorrabbin</name>
      <address>
        <city>east Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrew Love Cancer Care Centre, Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>8006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba Winnipeg</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital - Atlantic Health Sci</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <link>
    <url>http://www.trog.com.au</url>
    <description>Click here for more information about this study on the TROG official website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oesophageal</keyword>
  <keyword>Dysphagia</keyword>
  <keyword>Palliation</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deglutition Disorders</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

